| (INR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 91.50B | — |
| Operating expense | — | — |
| Net income | 10.33B | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, AUROPHARMA.NS returned +53.1% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +35.9% |
| 1 year | +53.1% |
| 5 years | +127.2% |
| 10 years | +114.0% |
| All-time high | ₹1,621.30 (Aug 2026) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what ₹1,000 in AUROPHARMA.NS would be worth today ›No. Aurobindo Pharma Limited has not paid a dividend in the past 12 months.
Aurobindo Pharma Limited is part of the Healthcare sector.
Aurobindo Pharma Limited has a market cap of 925.21B INR, based on the latest quote.
Aurobindo Pharma Limited is expected to report earnings around Nov 5, 2026. That date is an estimate and has not been confirmed by the company.
